Abstract
Molecular profiling, which is the application of molecular diagnostics technology to tissue and blood specimens, is an integral element in the new era of molecular medicine and individualized therapy. Molecular diagnostics is a fertile ground for small business development because it can generate products that meet immediate demands in the health-care sector: (a) Detection of disease risk, or early-stage disease, with a higher specificity and sensitivity compared to previous testing methods, and (b) “Companion diagnostics” for stratifying patients to receive a treatment choice optimized to their individual disease. This chapter reviews the promise and challenges of business development in this field. Guidelines are provided for the creation of a business model and the generation of a marketing plan around a candidate molecular diagnostic product. Steps to commercialization are outlined using existing molecular diagnostics companies as learning examples.
Key words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mamounas, E. P., Tang, G., Fisher, B., Paik, S., Shak, S., Costantino, J. P. et al. (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28, 1677–83.
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W. et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24, 3726–34.
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M. et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351, 2817–26.
American Hospital Association (2010) Fast Facts on US Hospitals. American Hospital Association: Chicago, IL, http://www.aha.org/aha/content/2010/pdf/101207fastfacts.pdf Accessed 16 February 2011
Batchelder, K., Miller, P. (2006) A change in the market--investing in diagnostics. Nat Biotechnol 24, 922–6.
Goldstein, D. B. (2010) Personalized medicine. Nature 463, 10.
Callaway, E. (2011) Cancer-gene testing ramps up. Nature 467, 766–7.
Collins, F. (2010) Has the revolution arrived? Nature 464, 674–5.
Hamburg, M. A., Collins, F. S. (2010) The path to personalized medicine. N Engl J Med 363, 301–4.
Taube, S. E., Jacobson, J. W., Lively, T. G. (2005) Cancer diagnostics: decision criteria for marker utilization in the clinic. Am J Pharmacogenomics 5, 357–64.
Schafer, J. C. (2007) Molecular Diagnostic Assays: Leading a High Value Evolutions. 2011, in Biotechnology Focus
Khoury, M. J., Evans, J. P., Burke, W. (2010) A reality check for personalized medicine. Nature 464, 680.
Doig, A. (2007) Molecular Diagnostics Market Assessment. Genetic Engineering & Biotechnology News 27, http://www.genengnews.com/gen-articles/molecular-diagnostics-market-assessment/2006/. Accessed 16 February 2011.
Sannes, L. (2007) Molecular Diagnostics: A Rapidly Shifting Commercial and Technology Landscape. in Insight Pharma Reports. Cambridge Healthtech Institute, 232.
Southern, E. M. (1974) An improved method for transferring nucleotides from electrophoresis strips to thin layers of ion-exchange cellulose. Anal Biochem 62, 317–8.
Leslie, D. E., Azzato, F., Ryan, N., Fyfe, J. (2003) An assessment of the Roche Amplicor Chlamydia trachomatis/Neisseria gonorrhoeae multiplex PCR assay in routine diagnostic use on a variety of specimen types. Commun Dis Intell 27, 373–9.
Whiley, D. M., Tapsall, J. W., Sloots, T. P. (2006) Nucleic acid amplification testing for Neisseria gonorrhoeae: an ongoing challenge. J Mol Diagn 8, 3–15.
Shah, S. S., Ketterling, R. P., Goetz, M. P., Ingle, J. N., Reynolds, C. A., Perez, E. A. et al. (2010) Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Hum Pathol 41, 103–6.
Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., Schnitt, S. J. (1999) Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17, 1983–7.
Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S. et al. (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134, e48-72.
Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M. et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–6.
van de Vijver, M. J., He, Y. D., Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W. et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999–2009.
Winter, P. (2009) Let’s make a deal. The Journal of Life Sciences 14–15.
Levine, D. S. (2009) A diagnosis of deals. The Journal of Life Sciences 12–13.
Meckley, L. M., Neumann, P. J. (2010) Personalized medicine: factors influencing reimbursement. Health Policy 94, 91–100.
Allegra, C. J., Aberle, D. R., Ganschow, P., Hahn, S. M., Lee, C. N., Millon-Underwood, S. et al. (2010) National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22–24, 2009. J Natl Cancer Inst 102, 161–9.
Kontos, E. Z., Viswanath, K. (2011) Cancer-related direct-to-consumer advertising: a critical review. Nat Rev Cancer 11, 142–50.
Farkas, D. H., Holland, C. A. (2009) Direct-to-consumer genetic testing: two sides of the coin. J Mol Diagn 11, 263–5.
Levine, D. S. (2007) Getting Personal. The Journal of Life Sciences 42–28.
Elkin, E. B., Weinstein, M. C., Winer, E. P., Kuntz, K. M., Schnitt, S. J., Weeks, J. C. (2004) HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22, 854–63.
Ferrusi, I. L., Marshall, D. A., Kulin, N. A., Leighl, N. B., Phillips, K. A. (2009) Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med 6, 193–215.
Hunt, P. W., Harrigan, P. R., Huang, W., Bates, M., Williamson, D. W., McCune, J. M. et al. (2006) Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 194, 926–30.
Daar, E. S., Lynn, H. S., Donfield, S. M., Lail, A., O’Brien, S. J., Huang, W. et al. (2005) Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression. J Infect Dis 192, 1597–605.
Vandekerckhove, L., Verhofstede, C., Demecheleer, E., De Wit, S., Florence, E., Fransen, K. et al. (2011) Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. J Antimicrob Chemother 66, 265–272.
Rader, R. A. (2010) FDA Biopharmaceutical Product Approvals and Trends: Significantly More Approvals Were Granted in 2009. Biotechnology Information Institute. http://www.biopharma.com/approvals_2009.html. Accessed 16 Feb 2011
Zenios, S., Chess, R. B., Denend, L. (2006) Genomic Health: Launching a Paradigm Shift…and an Innovative New Test (Case No: OIT49). Stanford Graduate School of Business: Palo Alto, CA, 1–36.
Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., Hortobagyi, G. N. (2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13, 477–93.
Farkas, D. H. (2008) Interview with Daniel H. Farkas, PhD, Executive Director of the Center for Molecular Medicine. Anagnostou, A., Rockville, telephone interview.
Farkas, D. H. (2008) Diagnostic Molecular Pathology in an Era of Genomics and Trans-lational Bioinformatics. Diagnostic Molecular Pathology 17, 1–2 10.1097/PDM.0b013e-31815dd481.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Anagostou, A., Liotta, L.A. (2012). Small Business Development for Molecular Diagnostics. In: Espina, V., Liotta, L. (eds) Molecular Profiling. Methods in Molecular Biology, vol 823. Humana Press. https://doi.org/10.1007/978-1-60327-216-2_28
Download citation
DOI: https://doi.org/10.1007/978-1-60327-216-2_28
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-215-5
Online ISBN: 978-1-60327-216-2
eBook Packages: Springer Protocols